Expertise in
16
conditions

Dr. Jeremy D. Rudnick

Neurology
23560 Crenshaw Blvd, 
Torrance, CA 
On Staff At
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
24 Years of Experience
Expertise in
16
conditions
23560 Crenshaw Blvd, 
Torrance, CA 

Overview

Jeremy Rudnick is a Neurologist practicing medicine in Torrance, California. He has been practicing medicine for over 24 years.

Dr. Rudnick is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

Dr. Rudnick is board certified in American Board Of Psychiatry & Neurology. He is actively involved in clinical research, co-authoring 17 peer reviewed articles and participating in 9 clinical trials.

Graduate Institution

State University Of New York College Of Medicine , 2002, 2002

Residency

University of California Los Angeles , Neurology , 2003 - 2006

Specialties

Neurology

Licenses

Psychiatry & Neurology in CA

Board Certifications

American Board Of Psychiatry & Neurology

Hospital Affiliations

Torrance Memorial Medical Center
Cedars-Sinai Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 2 Less Insurance Carriers -

Locations

Cedars Sinai Faculty Physicians
23560 Crenshaw Blvd, Torrance, CA 90505

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Drug: APL-101
Study Phase: Phase 2
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
Genomically-Guided Treatment Trial in Brain Metastases
Genomically-Guided Treatment Trial in Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Paxalisib, Entrectinib
Study Phase: Phase 2
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
Enrollment Status: Completed
Publish Date: March 05, 2026
Intervention Type: Other, Biological, Procedure, Drug, Radiation, Device
Study Drugs: Ipilimumab, Nivolumab, Temozolomide
Study Phase: Phase 2/Phase 3
A Phase 2 Study of Fluorescence Detection of Adult Primary Central Nervous System Tumors in Subjects Receiving Tozuleristide and Imaged With the Canvas System
A Phase 2 Study of Fluorescence Detection of Adult Primary Central Nervous System Tumors in Subjects Receiving Tozuleristide and Imaged With the Canvas System
Enrollment Status: Completed
Publish Date: June 13, 2025
Intervention Type: Drug, Procedure, Device
Study Drug: Tozuleristide
Study Phase: Phase 2
A Phase 1 Dose Escalation Trial of Neoadjuvant Radiosurgery for the Treatment of Metastatic Brain Tumors
A Phase 1 Dose Escalation Trial of Neoadjuvant Radiosurgery for the Treatment of Metastatic Brain Tumors
Enrollment Status: Active_not_recruiting
Publish Date: April 03, 2025
Intervention Type: Radiation, Procedure
Study Phase: Early Phase 1
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: April 03, 2024
Intervention Type: Biological
Study Phase: Phase 3
TOPAZ: Single Arm, Open Label Phase 1b/2 Study of Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases
TOPAZ: Single Arm, Open Label Phase 1b/2 Study of Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases
Enrollment Status: Withdrawn
Publish Date: July 01, 2022
Intervention Type: Drug
Study Drugs: Tucatinib, Pembrolizumab, Trastuzumab
Study Phase: Phase 1/Phase 2
A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma
A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma
Enrollment Status: Terminated
Publish Date: November 20, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

17 Total Publications

A phase 1 safety and feasibility trial of a ketogenic diet plus standard of care for patients with recently diagnosed glioblastoma.
A phase 1 safety and feasibility trial of a ketogenic diet plus standard of care for patients with recently diagnosed glioblastoma.
Journal: Scientific reports
Published: March 25, 2024
Similar Doctors
Expertise in
21
conditions
Dr. Timothy Cloughesy
Neurology
Expertise in
21
conditions
Dr. Timothy Cloughesy
Neurology

UCLA Health Bowyer Oncology Center

200 UCLA Medical Plz Ste 120, 
Los Angeles, CA 
 (18.8 miles away)
310-206-6909
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Timothy Cloughesy is a Neurologist practicing medicine in Los Angeles, California. Dr. Cloughesy is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

Expertise in
51
conditions
Dr. Susan Perlman
Neurology
Expertise in
51
conditions
Dr. Susan Perlman
Neurology

Office

300 Medical Plz, 
Los Angeles, CA 
 (18.4 miles away)
310-794-1195
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Susan Perlman is a Neurologist practicing medicine in Los Angeles, California. Dr. Perlman is highly rated in 51 conditions, according to our data. Her clinical expertise encompasses Spinocerebellar Ataxia, Friedreich Ataxia, Drug Induced Dyskinesia, and Olivopontocerebellar Atrophy.

Expertise in
24
conditions
Dr. Santosh Kesari
Neurology
Expertise in
24
conditions
Dr. Santosh Kesari
Neurology
2121 Santa Monica Boulevard, 
Santa Monica, CA 
 (17.0 miles away)
310-829-5511
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Santosh Kesari is a Neurologist practicing medicine in Santa Monica, California. Dr. Kesari is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, Brain Tumor, and Tissue Biopsy. Dr. Kesari is currently accepting new patients.

Frequently Asked Questions about Dr. Jeremy D. Rudnick

How do I make an appointment with Dr. Jeremy D. Rudnick?

You can book an appointment with Dr. Jeremy D. Rudnick by calling their office at 310-517-7022. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jeremy D. Rudnick a top-rated expert for Glioblastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jeremy D. Rudnick is classified as an Elite expert for Glioblastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jeremy D. Rudnick specialize in?

While Dr. Jeremy D. Rudnick is a Neurology, they have specific expertise in Glioblastoma, Astrocytoma, and Glioma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Jeremy D. Rudnick participate in research or clinical trials?

Yes. Dr. Jeremy D. Rudnick has published 17 articles and abstracts on conditions like Glioblastoma. You can view a list of Dr. Jeremy D. Rudnick's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jeremy D. Rudnick accept my insurance?

Dr. Jeremy D. Rudnick accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 310-517-7022 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rudnick's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 20 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile